Edgewise Therapeutics reported its fourth-quarter and full-year 2024 financial results along with recent business updates. The company completed enrollment for the GRAND CANYON global pivotal study of sevasemten in Becker muscular dystrophy and announced positive top-line results from the Phase 2 CANYON trial in Becker. It expects to release data from the Phase 2 CIRRUS-HCM trial of EDG-7500 in hypertrophic cardiomyopathy in the first quarter of 2025 and results from the Phase 2 LYNX and FOX trials in Duchenne muscular dystrophy in the first half of 2025.

Financially, Edgewise ended 2024 with $470.2 million in cash, cash equivalents, and marketable securities. Research and development expenses for Q4 2024 were $36.4 million, while general and administrative expenses totaled $9.2 million. The company reported a net loss of $39.7 million for the quarter, compared to $34.1 million in the previous quarter.

Edgewise remains focused on advancing its muscular dystrophy and cardiovascular programs, engaging with regulatory authorities, and continuing its outreach to the scientific and patient communities.